NRG5051 / NRG Therap - LARVOL DELTA

NRG5051-101: Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS (clinicaltrialsregister.eu) - P1 | N=110 | Recruiting | Sponsor: Nrg Therapeutics Limited

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • Movement Disorders • Parkinson's Disease

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s (GlobeNewswire) - "This Phase 1 randomized, double-blind trial is a combined single and multiple ascending dose trial of NRG5051 designed to assess safety, tolerability and pharmacokinetic parameters in healthy volunteers. It is being conducted at the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands1. The clinical trial is expected to readout by the end of 2026 and will inform dose selection in future studies in ALS/MND and Parkinson’s patients."

P1 data • Trial status • Amyotrophic Lateral Sclerosis • Parkinson's Disease

British biotechnology company NRG Therapeutics on Monday said it raised £50 million, or about $67 million, to advance its lead experimental medicine for neurodegenerative disorders into clinical testing. (BioPharma Dive) - "Preclinical testing gave the company hope its most advanced drug, a small molecule dubbed NRG-5051, might be able to reduce brain inflammation and treat Parkinson’s and ALS. With the new funding, the company aims to bring that therapy into clinical trials by early 2026."

Financing • New trial • Amyotrophic Lateral Sclerosis • Parkinson's Disease

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases (GlobeNewswire) - "NRG Therapeutics, Ltd...is pleased to announce that it has achieved a key milestone with the nomination of its first development candidate, NRG5051 and has been awarded a $5M grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. NRG5051 also has potential in other neurological diseases such as ALS (also known as MND)...In pre-clinical models of Parkinson’s and ALS, NRG5051 is neuroprotective and significantly reduces the neuroinflammation observed in these diseases. NRG’s grant from MJFF’s Therapeutics Pipeline Program will fund the completion of key IND-enabling studies with the aim of advancing NRG5051 into first-in-human clinical studies in 2025."

Financing • New trial • Pipeline update • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND (GlobeNewswire) - "NRG Therapeutics, Ltd...is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation...The funding will be used to support its discovery programme for a treatment for Amyotrophic Lateral Sclerosis...It has discovered a new class of small molecule mitochondrial permeability transition pore (mPTP) inhibitors that can block mitochondrial dysfunction...The In Vivo Target Validation Program aims to generate high-quality data on candidate therapeutics in animal models of ALS, provide access to in-kind funding for a resource-intensive step of drug discovery, and accelerate the progress of candidate therapeutics from preclinical testing towards clinical trials."

Financing • Amyotrophic Lateral Sclerosis • CNS Disorders

NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neuron Disease (PRNewswire) - "NRG Therapeutics Ltd...is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders....The £2.68 million early-stage BMC award part-funded by the government-backed agency Innovate UK will support a 24-month project, commencing this month."

Financing • CNS Disorders • Parkinson's Disease